{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:12:43Z","timestamp":1778199163840,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sponsored by Vigonvita Life Sciences Co., Ltd. and funded by the Noncommunicable Chronic Diseases-National Science and Technology Major Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02686-5","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:01:43Z","timestamp":1778198503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Yu-Ping","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Shan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9774-3980","authenticated-orcid":false,"given":"Dao-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Qing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Guo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-8773","authenticated-orcid":false,"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-0929","authenticated-orcid":false,"given":"Zhi-Cheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2686_CR1","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert, M. et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 61, 2200879 (2023).","journal-title":"Eur. Respir. J."},{"key":"2686_CR2","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun, P. M. Pulmonary arterial hypertension. N. Engl. J. Med. 385, 2361\u20132376 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2686_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","volume":"10","author":"A Mocumbi","year":"2024","unstructured":"Mocumbi, A. et al. Pulmonary hypertension. Nat. Rev. Dis. Prim. 10, 1 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2686_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1378\/chest.10-2327","volume":"140","author":"R Zhang","year":"2011","unstructured":"Zhang, R. et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 140, 301\u2013309 (2011).","journal-title":"Chest"},{"key":"2686_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper, M. M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478\u20131490 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2686_CR6","doi-asserted-by":"crossref","unstructured":"Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Respir. Med. 13, 69\u201379 (2025).","DOI":"10.3389\/fpubh.2025.1516365"},{"key":"2686_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-024-03169-2","volume":"30","author":"I Cheang","year":"2024","unstructured":"Cheang, I. et al. The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial. Nat. Med. 30, 2295\u20132302 (2024).","journal-title":"Nat. Med."},{"key":"2686_CR8","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2023.19524","volume":"330","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Traditional Chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: the CTS-AMI Randomized clinical trial. JAMA 330, 1534\u20131545 (2023).","journal-title":"JAMA"},{"key":"2686_CR9","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","volume":"69","author":"P Hao","year":"2017","unstructured":"Hao, P. et al. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J. Am. Coll. Cardiol. 69, 2952\u20132966 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2686_CR10","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1021\/jm301159y","volume":"55","author":"G Wang","year":"2012","unstructured":"Wang, G. et al. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. J. Med. Chem. 55, 10540\u201310550 (2012).","journal-title":"J. Med. Chem."},{"key":"2686_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107017","volume":"145","author":"C Zhao","year":"2022","unstructured":"Zhao, C. et al. TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats. Vasc. Pharm. 145, 107017 (2022).","journal-title":"Vasc. Pharm."},{"key":"2686_CR12","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.2147\/DDDT.S308610","volume":"15","author":"H Qian","year":"2021","unstructured":"Qian, H. et al. A phase I study to evaluate the safety, tolerability, and pharmacokinetics of TPN171H, a novel phosphodiesterase type 5 inhibitor, in healthy subjects. Drug Des. Devel. Ther. 15, 2947\u20132959 (2021).","journal-title":"Drug Des. Devel. Ther."},{"key":"2686_CR13","doi-asserted-by":"publisher","first-page":"119738","DOI":"10.1016\/j.jep.2025.119738","volume":"347","author":"S Wang","year":"2025","unstructured":"Wang, S. et al. Epimedium and its chemical constituents in cancer treatment: a comprehensive review of traditional applications, antitumor effects, pharmacokinetics, delivery systems, and toxicology. J. Ethnopharmacol. 347, 119738 (2025).","journal-title":"J. Ethnopharmacol."},{"key":"2686_CR14","doi-asserted-by":"crossref","unstructured":"Kenakin, T. P. Pharmacology in Drug Discovery and Development (Academic Press, 2017).","DOI":"10.1016\/B978-0-12-803752-2.00011-9"},{"key":"2686_CR15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8, N. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 373, 834\u2013844 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2686_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","volume":"83","author":"E Gr\u00fcnig","year":"2024","unstructured":"Gr\u00fcnig, E. et al. Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 83, 473\u2013484 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2686_CR17","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8, N. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894\u20132903 (2009).","journal-title":"Circulation"},{"key":"2686_CR18","first-page":"1488","volume":"44","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani, H. A. et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. 44, 1488\u20131496 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2686_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1183\/09031936.00039808","volume":"33","author":"F Grimminger","year":"2009","unstructured":"Grimminger, F. et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. 33, 785\u2013792 (2009).","journal-title":"Eur. Respir. J."},{"key":"2686_CR20","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s11030-024-11016-2","volume":"29","author":"MTM Nemr","year":"2024","unstructured":"Nemr, M. T. M., Abdelaziz, M. A., Teleb, M., Elmasry, A. E. & Elshaier, Y. An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors. Mol. Divers 29, 4765\u20134785 (2024).","journal-title":"Mol. Divers"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02686-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:01:45Z","timestamp":1778198505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02686-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2686"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02686-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hua-Qing Duan is employed by Vigonvita Life Sciences Co., Ltd., and the other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}